Cosmetic and regenerative peptides for skin, collagen and hair.
Skin, Hair & Aesthetic covers the cosmetic and regenerative peptides — copper peptides, matrikines, neuromodulating "topical Botox" peptides and hair-growth compounds. The defining distinction in this category is route: well-evidenced topical cosmetic use versus speculative injectable claims, which we keep rigorously separate.
An evidence-graded look at the melanocortin 'tanning peptides' — separating the one FDA-approved rare-disease drug (afamelanotide) from the unregulated, illegal-to-sell melanotan-2 'tan jabs' linked to melanoma, priapism and rhabdomyolysis.
A clinical look at copper peptides (GHK-Cu) and Matrixyl for striae distensae. No dedicated human trial exists for either — both grade D for stretch marks specifically, despite stronger data on other skin.
Skin, Hair & AestheticAn evidence-graded look at the melanocortin peptides marketed for a tan or 'natural photoprotection' — separating the one FDA-approved rare-disease drug (afamelanotide) from the unregulated, illegal-to-sell melanotan products linked to melanoma and priapism.
Skin, Hair & AestheticA master, evidence-graded overview of the aesthetic peptide field — GHK-Cu, Matrixyl, Argireline, Synthe'6 and the neuromodulator cast — separating small topical human RCTs from in-vitro mechanism and marketing. The honest ceiling is Grade B.
Skin, Hair & AestheticWhich cosmetic peptides actually soften wrinkles and photoaging — GHK-Cu, Matrixyl, argireline and more — ranked honestly by the human evidence. All are Grade B: modest, topical, delivery-limited, none Grade A.
Skin, Hair & AestheticAn evidence-graded ranking of the peptides marketed for hair thinning, density, and shedding — separating the modest human topical data from the mechanistic and mouse-only hype.
Skin, Hair & AestheticAn evidence-graded ranking of the peptides marketed for androgenetic alopecia — zinc-thymulin, biotinoyl tripeptide-1/Procapil, GHK-Cu copper peptide, and PTD-DBM — separating the small human data from mouse work, blends, and marketing.
Skin, Hair & AestheticA clinical, evidence-first ranking of the peptides marketed for hair regrowth — zinc-thymulin, copper peptides, biotinoyl tripeptide-1 (Procapil) and PTD-DBM — graded honestly, with human versus preclinical evidence kept strictly separate.
Skin, Hair & AestheticAn evidence-graded ranking of the topical matrikine and copper peptides marketed for collagen, elastin and firmness — GHK-Cu, Matrixyl, palmitoyl tripeptide-1 and Synthe'6 — separating small human RCTs from in-vitro mechanism and marketing.
Skin, Hair & AestheticAn evidence-graded ranking of the peptides marketed for cellulite — oral collagen peptides, GHK-Cu, AOD-9604 and HGH Fragment 176-191 — separating the one modest human signal from mechanism, marketing and WADA-banned research chemicals.
Skin, Hair & AestheticAn evidence-graded ranking of the peptides studied for atrophic acne scarring — copper tripeptide, the TriHex matrikine blend, and Matrixyl — separating the small human adjunct data from in-vitro mechanism and marketing.
Some have modest, formulation-dependent topical evidence. Matrikine peptides such as Matrixyl (palmitoyl pentapeptide-4) and neuromodulating peptides like argireline have human cosmetic studies showing small reductions in wrinkle depth or expression lines, with effects that depend heavily on concentration and skin penetration. The effects are real but generally modest — far smaller than injectable neurotoxin or filler procedures. We grade each claim to the actual study quality.
No, and conflating them is a common error. Topical copper tripeptide (GHK-Cu) has reasonable human cosmetic evidence for skin and hair. Injectable GHK-Cu is a different proposition: it was placed on the FDA 503A Category 2 list and its systemic use is largely speculative, without the human evidence that supports topical use. We keep the well-evidenced topical applications clearly separated from the speculative injectable claims.
Topical copper peptides and a few experimental hair peptides show follicle-supportive effects in limited studies, but the evidence is far thinner than for established treatments such as minoxidil or finasteride. Several hair peptides discussed here rest on small or preclinical data. We are explicit about evidence strength and never imply a peptide matches the proven hair-loss therapies unless the human data support it.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
